Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [7] It is taken by mouth. [7]Molnupiravir is a prodrug of the synthetic nucleoside derivative N 4-hydroxycytidine and exerts its antiviral action by …

Lagevrio FDA Approval Status. Last updated by Judith Stewart, BPharm on April 4, 2022.. FDA Approved: No (Emergency Use Authorization) Brand name: Lagevrio Generic name: molnupiravir Dosage form: Capsules Company: Merck Treatment for: COVID-19 Lagevrio (molnupiravir) is an investigational oral antiviral agent for the treatment of COVID-19.. The U.S. FDA has issued an EUA for the emergency use ...

2023年8月23日 · Molnupiravir is an experimental medicine being studied for the treatment of mild-to-moderate COVID-19. Includes molnupiravir side effects, interactions, and indications.

Pharmacokinetics. Following oral administration of the prodrug molnupiravir capsule to healthy volunteers in the fasted state, NHC reaches peak concentrations at approximately 1.5 h following dose administration and then declines in a biphasic manner (Figure 3). 9 Very little molnupiravir prodrug is detected in plasma. Circulating NHC exposures increased in a manner that is approximately ...

2021年11月23日 · Molnupiravir,EIDD,2801MK,4482,由默沙东及Ridgeback联合研发,是一种可口服的核糖核苷类似物,可抑制包括SARS,CoV,2,新冠病毒的致病因子,在内的多种RNA病毒的复制

Molnupiravir is an oral ribonucleoside analog, which means it is similar in structure to one of the building blocks of RNA, a molecule that is important for the replication of viruses such as SARS-CoV-2 [].N4-hydroxycytidine (NHC, EIDD 1921) is a new isobutyryl ester prodrug that has been tested in phase II and III studies to treat SARS-CoV-2 infection [].

Adverse Events. Molnupiravir was well tolerated in patients with COVID-19 in clinical trials [18, 19, 34, 37].In a phase I trial (NCT04746183), outpatients with COVID-19 received molnupiravir 300–800 mg twice daily for 5 days plus standard-of-care or standard-of-care alone (control) [].A molnupiravir dose was deemed unsafe if the probability …

Molnupiravir comes as a capsule to take by mouth. It is usually taken with or without food two times a day for 5 days. Take molnupiravir at around the same times every day.

2022年1月31日 · Molnupiravir is a ribonucleoside analogue and antiviral agent that is used in the therapy the severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection, the cause of the novel coronavirus disease, 2019 (COVID-19). Molnupiravir therapy is given orally for 5 days early in the course of SARS-CoV-2 infection and has not been linked to serum aminotransferase elevations or to ...

2024年6月1日 · As a result of encouraging outcomes of a planned interim analysis from the Phase III MOVe-OUT clinical trial, On 11th October 2021, Merck applied for an emergency use authorization (EUA) to both the Food and Drug Administration (FDA) and the FDA's Antimicrobial Drugs Advisory Committee (AMDAC) at the Center for Drug Evaluation and Research [23], [24].